Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

The order followed the company’s assurance that it would not market any anti-obesity products in India until the patent lapses. The court had granted similar relief to Dr Reddy’s Laboratories earlier ...

James Corden admitted he ditched Ozempic last year after it failed to curb his eating habits - but his lookalike sister, Ruth ...

Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo Nordisk A/S (NYSE:NVO) to Hold from Buy on December 8, without assigning a ...

Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to buy heading into 2026. On December 5, Kerry Holford, an analyst at Berenberg Bank, reaffirmed the ‘Buy’ rating on Novo Nordisk A/S ...

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Sun Pharma, like Dr Reddy's Lab, can't sell semaglutide-based products in India until March 2026 when Novo Nordisk’s patent expires ...

Novo Nordisk, a Danish pharmaceutical company, has approached the Delhi High Court to prevent Sun Pharmaceutical from handling semaglutide, a key ingredient in the drug Ozempic.

US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.EXTON, PA, Dec. 09, 2025 (GLOBE ...